XML 36 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Data
 9 Months Ended
Jun. 24, 2016
Segment Reporting [Abstract]  
Segment Data
18.
Segment Data
On November 27, 2015, the Company completed the sale of the CMDS business to Guerbet. As a result, the CMDS business was eliminated from the Global Medical Imaging segment, which has been renamed Nuclear Imaging.
Prior year amounts have been recast to conform to current presentation.
The three reportable segments are further described below:
•
Specialty Brands produces and markets branded pharmaceutical and biopharmaceutical products and therapies;
•
Specialty Generics produces specialty generic pharmaceuticals and API consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients; and
•
Nuclear Imaging manufactures and markets radiopharmaceuticals (nuclear medicine).

Selected information by business segment was as follows:

Three Months Ended
 
Nine Months Ended

June 24,
2016

June 26,
2015
 
June 24,
2016
 
June 26,
2015
Net sales:



 
 
 
 
Specialty Brands
$
589.3


$
446.2

 
$
1,667.5

 
$
1,154.1

Specialty Generics
263.4

 
307.9

 
785.4

 
954.9

Nuclear Imaging
104.0


108.8

 
309.8

 
320.2

Net sales of operating segments
956.7


862.9

 
2,762.7

 
2,429.2

Other (1)
13.9


14.4

 
40.7

 
35.3

Net sales
$
970.6


$
877.3

 
$
2,803.4

 
$
2,464.5

Operating income:



 
 
 
 
Specialty Brands
$
305.5


$
189.2

 
$
840.6

 
$
434.8

Specialty Generics
101.2

 
157.2

 
321.0

 
501.4

Nuclear Imaging
22.6


23.8

 
68.7

 
47.4

Segment operating income
429.3


370.2

 
1,230.3

 
983.6

Unallocated amounts:





 
 
 
 
Corporate and allocated expenses (2)          
(35.3
)

(71.4
)
 
(110.4
)
 
(210.7
)
Intangible asset amortization
(175.8
)

(149.0
)
 
(524.2
)
 
(396.7
)
Restructuring and related charges, net (3)
(15.3
)

(22.7
)
 
(32.1
)
 
(33.6
)
Non-restructuring impairment charges
—

 
—

 
(16.9
)
 
—

Operating income
$
202.9

 
$
127.1

 
$
546.7

 
$
342.6


(1)
Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
(2)
Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
(3)
Includes restructuring-related accelerated depreciation.

Net sales by product family within the Company's segments are as follows:
 
Three Months Ended
 
Nine Months Ended
 
June 24, 2016
 
June 26, 2015
 
June 24, 2016
 
June 26, 2015
Acthar
$
298.3

 
$
268.7

 
$
833.4

 
$
763.1

Inomax
121.1

 
81.5

 
347.4

 
81.5

Ofirmev
70.7

 
62.1

 
208.7

 
201.6

Therakos immunotherapy
52.5

 
—

 
153.1

 
—

Hemostasis products
13.9

 
—

 
25.3

 
—

Other
32.8

 
33.9

 
99.6

 
107.9

Specialty Brands
589.3

 
446.2

 
1,667.5

 
1,154.1

 
 
 
 
 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
38.2

 
37.4

 
115.7

 
138.0

Oxycodone (API) and oxycodone-containing tablets
30.6

 
31.6

 
97.4

 
127.2

Methylphenidate ER
24.3

 
30.0

 
80.1

 
112.6

Other controlled substances
124.7

 
157.4

 
356.3

 
414.7

Other
45.6

 
51.5

 
135.9

 
162.4

Specialty Generics
263.4

 
307.9

 
785.4

 
954.9

 
 
 
 
 
 
 
 
Nuclear Imaging
104.0

 
108.8

 
309.8

 
320.2

 
 
 
 
 
 
 
 
Other (1)
13.9

 
14.4

 
40.7

 
35.3

Net sales
$
970.6

 
$
877.3

 
$
2,803.4

 
$
2,464.5


(1)
Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.